Biotechnology · San Diego, California, United States
$12.40
+5.35% (+$0.63)2026-08-24
Smart-Money SignalNeutral · 49/100— Insiders are net buyers over 90 days ($1.1M, 3 buys vs 3 sales)
Revenue$20.9M
Net Income-$68.3M
EPS$-1.60
Market Cap$1.1B
Price Performance
Historical data including institutional events
Company Profile
T
Troy Wilson
CEO & Executive Director
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
The company is headquartered in San Diego, California.
